Matthew Bailey, PharmD Candidate

Cyclin-Dependent Kinase 4/6 Inhibitors, Margetuximab, Trastuzumab Deruxtecan, and Tyrosine Kinase Inhibitors Have Shown Promising Results

Some patients are hesitant to use this class of drugs because of the stigma of potential addiction.

The number of individuals diagnosed with cancer steadily increases each year.

Cancer is the second-leading cause of death in the United States.